Clinical trials: Neovascularization, Pathologic
Choroidal Neovascularization, Myopia
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes.
- Conditions
- Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC), Multifocal Choroiditis
- Trial name
- CNV (NCT01256580)
- Testing
- Bevacizumab (Avastin; Genentech, Inc.), Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
- Sponsor
- Massachusetts Eye and Ear Infirmary
Neovascularization, Tuberculosis
Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
One complication of uveitis which is driven by an increase in VEGF is the formation of inflammatory ocular neovascularization (ION).
- Conditions
- Neovascularization, Tuberculosis, Multifocal Serpiginous Choroiditis, Harada Toxoplasmosis
- Trial name
- AVA-ION (NCT00645697)
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in…
- Trial name
- STAIRWAY (NCT03038880)
- Testing
- Faricimab, Ranibizumab
- Where
- 25 sites in United States
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Age-related Macular Degeneration
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the…
- Trial name
- NCT01350323
- Testing
- Aqueous sample
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Molise
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
- Trial name
- PALLAS (NCT07389980)
- Testing
- aflibercept 8 mg
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
The study will evaluate the efficacy and safety of two different regimens of anti-VEGF Therapy (OCTA plus OCT guided 3+PRN vs. OCT guided 3+PRN) in Chinese patients with PCV.
- Trial name
- NCT04380974
- Testing
- OCTA plus OCT guided 3+PRN regimen, OCT guided 3+PRN regimen, Anti-VEGF drug
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Xiaodong Sun
Age Related Macular Degeneration
PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
The primary objective of this study is to assess the ability of the PHP \& HPHP to detect newly diagnosed non treated Chorodial neovascularization (CNV) lesion associate with advanced age related Macular Degeneration (AMD) and…
- Trial name
- NCT00359008
- Where
- Israel
- Volunteers
- 336 people
- Sponsor
- Notal Vision Ltd.
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Corneal Neovascularization
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
- Trial name
- NCT00681889
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Reza Dana, MD
Conjunctivitis, Glaucoma
Feasibility Study and Preliminary Application Study on Iris OCTA
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
- Conditions
- Conjunctivitis, Glaucoma, Myopia, Diabetic Retinopathy
- Trial name
- NCT03631108
- Testing
- OCTA (ZEISS)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Macular Degeneration, Choroidal Neovascularization
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina.
- Trial name
- NCT00509548
- Testing
- TG100801
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- TargeGen
Macular Degeneration, Histoplasmosis
Submacular Surgery Trials (SST)
To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV…
- Trial name
- NCT00000150
- Testing
- Subfoveal Choroidal Neovascularization Removal
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University
Age-Related Macular Degeneration
Genetic Study of Age-Related Macular Degeneration
This study will examine skin and blood cells for genetic changes related to the development of age-related macular degeneration, an eye disease that can significantly impair the ability to read, drive, and carry out daily…
- Trial name
- NCT00357578
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Diabetic Retinopathy, Retinal Neovascularization
Krypton-Argon Regression of Neovascularization Study (KARNS)
To evaluate whether red krypton laser treatment is as effective at causing regression of diabetic disc neovascularization as treatment with the blue-green argon laser, when both lasers are used with identical panretinal…
- Conditions
- Diabetic Retinopathy, Retinal Neovascularization, Diabetes Mellitus
- Trial name
- NCT00000153
- Testing
- Blue-Green Argon Laser Treatment, Red Krypton Laser Treatment
- Sponsor
- National Eye Institute (NEI)
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York